Amgen And Allergan File For US Rituximab

Submission Supported by Two Comparative Studies

 
• By Aidan Fry
  
Amgen
Amgen has filed with the FDA for approval of its ABP798 rituximab biosimilar candidate • Source: Shutterstock

More from Biosimilars

More from Products